# A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

> **NCT05508334** · PHASE1,PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** RC88

## Key facts

- **NCT ID:** NCT05508334
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-30
- **Primary completion:** 2025-11-26
- **Final completion:** 2025-11-26
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05508334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05508334, "A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05508334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*